Pending Merger, Archemix Inks Potential $1.4B Deal with GSK

Archemix Corp. and London-based GlaxoSmithKline plc agreed to discover, develop and commercialize aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, in a collaboration that gives Archemix

Leave a Reply